Javier Martin-Broto, MD, PhD

home / authors / javier-martin-broto-md-phd

Articles

Javier Martín Broto MD, PhD

Dr Martín-Broto on the Efficacy of Sunitinib Plus Nivolumab in Clear Cell Sarcoma

Javier Martin-Broto, MD, PhD
October 8th 2024

Javier Martín Broto MD, PhD, discusses the efficacy of treatment with sunitinib plus nivolumab in clear cell sarcoma, according to the IMMUNOSARC II trial.

Read More

Javier Martin-Broto, MD, PhD,

Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma

Javier Martin-Broto, MD, PhD
September 8th 2022

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

Read More

Javier Martin-Broto, MD, PhD

Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas

Javier Martin-Broto, MD, PhD
August 31st 2022

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

Read More

Javier Martin-Broto, MD, PhD

Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma

Javier Martin-Broto, MD, PhD
June 15th 2022

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.

Read More

Javier Martin-Broto, MD, PhD

Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma

Javier Martin-Broto, MD, PhD
June 15th 2022

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC